Sample Size Expert Blog

5 Reasons Why Pharma Companies Are Calculating Bayesian Assurance

The pharmaceutical industry is increasingly turning to Bayesian methods in an attempt to improve efficiency and enhance decision making. Assurance (Bayesian Power) is becoming a key feature of these Bayesian methods. This is not to replace traditional power but to complement it.

Topics: Clinical Trials Bayesian Assurance nQuery Bayes sample size determination

Dose Escalation: Quickly determine the Maximum-Tolerated Dose through Continual Reassessment Method

A key drawback of the traditional 3+3 design in dose escalation is its slow processing of data to reach the target dose. In contrast, the Continual Reassessment Method designs produce an expedited convergence to the target dose or the doses near target.

Topics: Clinical Trials Dose Escalation Continual Reassessment Method (CRM)

Why Frequentists are using Bayesian Statistics in Clinical Trial Design

Statisticians are familiar with the long standing debate regarding Frequentists Vs Bayesian methodologies and the benefits (or negatives) that each present to a particular situation. However, we are now experiencing a rise in traditional frequentists using Bayesian statistics. What are the reasons behind this? While complex, we can identify two high level points.

Topics: Clinical Trials Bayesian Assurance nQuery Bayes

Top 10 Corporate Clinical Trial Sponsors of 2016

Following on from our previous blog post, The Most Popular Clinical Trial Drugs of 2016, we thought it would be a good idea to take a closer look at the Top 10 Corporate Clinical Trial Sponsors of 2016.

In this post, we explore these Top 10 companies, looking at their developmental histories as well as the drugs they have developed and the number of subjects required for their 2016 registered trials.

Topics: Power & Sample Size Clinical Trials Clinical Trial Sponsors Top10

Wider Integration of Cost Considerations in Sample Size

In part 3/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.

Topics: Power & Sample Size cost consideration, integration

The Effect of Adaptive Trials and Sample Size Re-estimation

In part 2/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.

Topics: Power & Sample Size adaptive trials sample size restimation

Integrating Uncertainty in Parameter Estimates

In part 1/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.

Topics: Power & Sample Size Parameter Estimates

Most Popular Clinical Trial Drugs of 2016

Currently there are over 205,000 registered clinical trials underway throughout the globe. In 2016 over 14,000 new trials were initiated and we thought it would be useful to look at the top drugs under investigation for the year just past.

Topics: Power & Sample Size Phase III Failure